NCT02530476 - Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 8, 2015

Primary Completion Date

April 8, 2019

Study Completion Date

April 8, 2019

Conditions

LeukemiaAcute Myeloid Leukemia

Interventions

DRUG

Selinexor

"Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."

DRUG

Sorafenib

"Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston